Pirtobrutinib Produces Durable Responses in Relapsed/Refractory MCL
Pirtobrutinib has shown clinical activity in a phase 1/2 trial of patients with relapsed or refractory mantle cell lymphoma.
All articles by Julie Ehlers
Testing for ESR1 Mutations Recommended in HR+, HER2- Metastatic Breast Cancer
Routine testing for ESR1 mutations should occur upon recurrence or progression of HR+, HER2- metastatic breast cancer, a guideline suggests.
No Benefit With Atezolizumab in BRCA1/2-Mutant or HRD Ovarian Cancer
Adding atezolizumab to standard treatment did not improve PFS in patients with advanced ovarian cancer and BRCA1/2 mutations or HRD.
About 20% of Oncologists Studied Left Patient-Facing Positions Between 2015 and 2022
In a study of 16,870 oncologists practicing in the United States, 21% left patient-facing roles between 2015 and 2022.
Maveropepimut-S Plus Cyclophosphamide Yields Responses in Recurrent Ovarian Cancer
The combination of maveropepimut-S and cyclophosphamide has shown activity in patients with recurrent ovarian cancer, a study suggests.
Heart Failure Rates After Carfilzomib Similar in Black and White MM Patients
New research suggests that carfilzomib increases the risk of heart failure in patients with multiple myeloma, but the risk does not appear to vary between Black and White patients.
Belantamab Mafodotin Deemed Safe, Effective in Real-World MM Population
Belantamab mafodotin has shown clinical activity and a manageable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma.
Pediatric Cancer Survivors Have 4-Fold Higher Risk of Death 40 Years After Diagnosis
From 15 to 40 years after diagnosis, pediatric cancer survivors have a roughly 4-fold higher risk of death than the general population, a study suggests.
Adding Ipilimumab to Nivolumab Provides No Benefit in Recurrent or Metastatic HNSCC
Adding ipilimumab to treatment with nivolumab does not improve response or survival outcomes in recurrent/metastatic HNSCC, a phase 2 trial suggests.
Belzutifan Plus Cabozantinib Deemed Promising for Advanced RCC
Combination treatment with belzutifan and cabozantinib has demonstrated antitumor activity in previously treated, advanced clear cell renal cell carcinoma.
- Loading...
Loading...
Next post in Renal Cell Carcinoma
Loading... 
Loading...